laura esserman
University of California, San Francisco
H-index: 96
North America-United States
Top articles of laura esserman
Title | Journal | Author(s) | Publication Date |
|---|---|---|---|
Duration of Endocrine Treatment for DCIS impacts second events: Insights from a large cohort of cases at two academic medical centers | Research Square | Thomas O’Keefe Christina Yau Emma Iaconetti Eliza Jeong Case Brabham | 2024/1/11 |
Reproductive rights in the United States: acquiescence is not a strategy | Nature Medicine | Laura J Esserman Douglas Yee | 2024/4/25 |
High IL12family levels are associated with pathologic complete response amongst HER2-patients in the neoadjuvant I-SPY2 TRIAL | Cancer Research | Kingsley V Chow Silver Al Khafaji Denise Wolf Christina Yau Kailey Dubinsky | 2024/3/22 |
Breast cancer-response prediction subtypes | 2024/2/22 | ||
Abstract A059: Heterogeneous cell populations in organoid models derived from breast preinvasive and invasive carcinomas after endocrine therapy | Cancer Research | Nadine Goldhammer Shruti Warhadpande Liana Beld Cristian K Maldonado Rodas Allison Lam | 2024/2/1 |
Abstract A026: An alternative to HER2 IHC 0/1+/2+ status to predict which clinically HER2-negative patients will respond to anti-HER2 therapies: A rationale for the likely … | Cancer Research | Julia Wulfkuhle Denise M Wolf Angela DeMichele Christina Yau Laura van ‘t Veer | 2024/2/1 |
Precision Oncology in Breast Cancer Surgery | Ali Benjamin Abbasi Vincent Wu Julie E Lang Laura J Esserman | 2024/1/9 | |
Epithelial Expressed B7-H4 Drives Differential Immunotherapy Response in Murine and Human Breast Cancer | Cancer Research Communications | Elizabeth C Wescott Xiaopeng Sun Paula Gonzalez-Ericsson Ann Hanna Brandie C Taylor | 2024/4/24 |
Abstract A032: Low non-immune stromal cell levels and high hypoxic tumor microenvironments are associated with pathologic complete response in the neoadjuvant I-SPY2 TRIAL | Cancer Research | Kailey Dubinsky Elene Tsopurashvili Denise M Wolf Zheyun Xu Silver Al Khafaji Alkhafaji | 2024/2/1 |
Immune subtyping identifies a subset of HR+ HER2-early-stage breast cancer patients with a very high likelihood of response to neoadjuvant immunotherapy (IO): Results from 5 IO … | Cancer Research | Denise M Wolf Christina Yau Lajos Pusztai Rita Nanda Jo Chien | 2024/3/22 |
Novel subtypes of severe COVID-19 respiratory failure based on biological heterogeneity: a secondary analysis of a randomized controlled trial | Critical Care | Narges Alipanah-Lechner James Hurst-Hopf Kevin Delucchi Lamorna Swigart Andrew Willmore | 2024/2/21 |
Abstract PR07: Intratumoral injection of mRNA-2752 and anti-PD-1 results in rapid regression of HER2 positive and or Hormone Receptor Negative DCIS: Phase 1 study results | Cancer Research | Laura J Esserman Kirithiga Ramalingam Rachel Woody Alexa Glencer Christopher Schwartz | 2024/2/1 |
Characterizing attitudes related to future child-bearing in young women diagnosed with early-stage breast cancer | Breast Cancer Research and Treatment | Saumya Umashankar Moming Li Kaylee Blevins Mi-Ok Kim Melanie Majure | 2024/1/9 |
Cell-free DNA concentration as a biomarker of response and recurrence in HER2-negative breast cancer receiving neoadjuvant chemotherapy | Clinical Cancer Research | Mark Jesus M Magbanua Ziad Ahmed Rosalyn W Sayaman Lamorna Brown Swigart Gillian L Hirst | 2024/4/10 |
Abstract A014: Cell-free DNA concentration as a biomarker of response and recurrence in HER-2 negative breast cancer receiving neoadjuvant chemotherapy | Cancer Research | Mark Jesus M Magbanua Ziad Ahmed Rosalyn W Sayaman Lamorna Brown-Swigart Gillian L Hirst | 2024/2/1 |
Beyond detection: AI-based classification of breast cancer invasiveness using cell-free orphan non-coding RNAs | Cancer Res | Mehran Karimzadeh Taylor B. Cavazos Nae-Chyun Chen Noura K. Tbeileh David Siegel | 2024 |
Abstract B084: Association between race and ethnicity, area deprivation, and exposure to environmental toxins in the WISDOM clinical trial population | Cancer Research | Katherine E Leggat-Barr Kimberly Badal Allison Stover-Fiscalini Dan Meltzer Mindy Hebert-DeRouen | 2024/2/1 |
Neoadjuvant trebananib plus paclitaxel-based chemotherapy for stage II/III breast cancer in the adaptively randomized I-SPY2 trial—Efficacy and biomarker discovery | Clinical Cancer Research | Kathy S Albain Christina Yau Emanuel F Petricoin Denise M Wolf Julie E Lang | 2024/2/16 |
Systematic annotation of orphan RNAs reveals blood-accessible molecular barcodes of cancer identity and cancer-emergent oncogenic drivers | bioRxiv | Jeffrey Wang Jung Min Suh Brian J Woo Albertas Navickas Kristle Garcia | 2024 |
Neoadjuvant Chemotherapy and Immunotherapy for Estrogen Receptor-Positive Human Epidermal Growth Factor 2-Negative Breast Cancer | Journal of clinical oncology: official journal of the American Society of Clinical Oncology | Alejandro Ríos-Hoyo Erin Cobain Laura A Huppert Peter D Beitsch Thomas A Buchholz | 2024/4/9 |
